Licensed breast cancer Rigel has recently launched VEPPANU (vepdegestrant) in the US and secured an exclusive global license with Arvinas and Pfizer to develop, manufacture, and commercialize it. Sales opportunities exist in expanding access through partnerships, oncology specialty channels, and payer strategies to support uptake of this ER-positive, ESR1-mutated breast cancer therapy.

Q2 revenue momentum Strong quarterly performance with $78.7 million in revenue and evidence of rising US net product sales. Leverage this trajectory to position complementary hematologic and cancer assets to pipeline stakeholders, payers, and IDNs seeking integrated oncology solutions.

Strategic partnerships Onco360 partnership for VEPPANU indicates a channel strategy with specialty pharmacies. There are opportunities to expand distribution through additional specialty channels, genomics-guided treatment programs, and ER-positive/HER2-negative breast cancer care networks.

Global license potential Exclusive global licensing deal for VEPPANU suggests Rigel is open to strategic collaborations. BD efforts could target co-development, manufacturing, and regional commercialization agreements in geographies with high ER-positive breast cancer prevalence.

Clinical and tech readiness Rigel’s tech stack includes AI and cloud tools (Azure AI Services, OpenAI, SageMaker) indicating data-driven research and real-world evidence capabilities. Position offerings that accelerate biomarker-driven trials, real-world evidence gathering, and post-market surveillance to support product optimization and payer value dossiers.